Close

Novo Nordisk (NVO) Receives Positive CHMP Opinion for Marketing of Fiasp as Diabetes Treatment

Go back to Novo Nordisk (NVO) Receives Positive CHMP Opinion for Marketing of Fiasp as Diabetes Treatment